Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4)

Frederick Kaskel,	M.D.,	Ph.	D.
-------------------	-------	-----	----

Committees: Cardiovascular and Renal Drugs and the Drug Safety and Risk Management

Advisory Committees

Meeting Date: September 11, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to the discussions of updated information on risks and benefits of erythropoiesis-stimulating agents, when used in the treatment of anemia due to chronic renal failure, I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude		
Stock	Affected Firm	Valued from \$5,001 to \$25,000		
Stock	Affected Firm	Valued from \$5,001 to \$25,000		
I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.				
/S/_Signature of SGE	<u>07/27/07</u> Date	-		